nach oben

Graefe's Archive for Clinical and Experimental Ophthalmology

Erschienen in:

01.01.2012 | Glaucoma

Randomized crossover study of latanoprost and travoprost in eyes with open-angle glaucoma

verfasst von: Akira Sawada, Tetsuya Yamamoto, Naoyoshi Takatsuka

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Introduction

To compare the intraocular pressure (IOP)-lowering effects of 0.005% latanoprost to that of 0.004% travoprost in eyes with open-angle glaucoma (OAG).

Methods

Forty-two patients with OAG who received either latanoprost or travoprost every evening for 12 weeks, and then switched to the other medication for another 12 weeks. The IOP measurements were made with a Goldmann applanation tonometer (GAT) at the baseline, and at 1, 3, 4, and 6 months after the treatment. The IOP at the untreated baseline and at the end of each treatment period was measured at 10:00, 12:00, and 16:00 hours. The central corneal thickness (CCT) was measured at each visit using an ultrasonic pachymeter.

Results

The mean baseline IOP was 13.9 ± 2.5 mmHg, and the CCT was 536.7 ± 30.5 μm. Latanoprost reduced the IOP by 2.5 ± 1.7 mmHg and travoprost by 2.6 ± 1.5 mmHg from the baseline (p = 0.6807). The CCT decreased significantly to 531.9 ± 30.3 at 3 months (p = 0.0160) and to 529.4 ± 30.5 μm at 6 months (p = 0.0002) after the therapy. The decrease was significantly greater in eyes after travoprost (p = 0.0049).

Conclusions

Travoprost has similar effect as latanoprost in reducing the IOP in glaucoma patients with relatively low IOPs. The use of prostaglandin analogs can decrease the CCT, and this change should be considered when the IOPs obtained by GAT are analyzed.

Iwase A, Suzuki Y, Araie M, Yamamoto T, Abe H, Shirato S, Kuwayama Y, Mishima HK, Shimizu H, Tomita G, Inoue Y, Kitazawa Y, Tajimi Study Group, Japan Glaucoma Society (2004) The prevalence of primary open-angle glaucoma in Japanese. The Tajimi Study. Ophthalmology 111:1641–1648PubMed

Collaborative Normal-Tension Glaucoma Study Group (1998) Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 126:487–497CrossRef

Gross RL, Peace JH, Smith SE, Walters TR, Dubiner HB, Weiss MJ, Ochsner KI (2008) Duration of IOP reduction with travoprost BAK-free solution. J Glaucoma 17:217–222PubMedCrossRef

Chew PT, RojanaPongpun P, Euswas A, Lu D, Chua J, Hui S, Rait J, Goldberg I, Li B, Travatan CACG Study Group (2006) Intraocular pressure-lowering effect and safety of travoprost 0.04% and latanoprost 0.005% for the treatment of chronic angle closure glaucoma. Asian J Ophthalmol 8:13–19

Netland PA, Landry T, Sullivan EK, Andrew R, Silver L, Weiner A, Mallick S, Dickerson J, Bergamini MV, Robertson SM, Davis AA, Travoprost Study Group (2001) Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 132:472–484PubMedCrossRef

Arcieri ES, Pierre Filho PT, Wakamatsu TH, Costa VP (2008) The effects of prostaglandin analogues on the blood aqueous barrier and corneal thickness of phakic patients with primary open-angle glaucoma and ocular hypertension. Eye 22:179–183PubMedCrossRef

Bean GW, Camras CB (2008) Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences. Surv Ophthalmol 53(suppl 1):S69–S84PubMedCrossRef

Maul E, Carrasco FG, Costa VP, Casiraghi JF, Vargas E, Sarmina JS, Mayol R (2007) A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%. Clin Ther 29:1915–1923PubMedCrossRef

Hepsen IF, Ozkaya E (2007) 24-h IOP control with latanoprost, travoprost, and bimatoprost in subjects with exfoliation syndrome and ocular hypertension. Eye 21:453–458PubMed

10.

García-Feijoo J, Martínez-de-la-Casa JM, Castillo A, Méndez C, Fernández-Vidal A, García-Sánchez J (2006) Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%. Curr Med Res Opin 22:1689–1697PubMedCrossRef

11.

Dubiner HB, Sircy MD, Landry T, Bergamini MV, Silver LH, Darell Turner F, Robertson S, Andrew RM, Weiner A, Przydryga J (2004) Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost. Clin Ther 26:84–91PubMedCrossRef

12.

Yan DB, Battista RA, Haidich AB, Konstas AG (2008) Comparison of morning versus evening dosing and 24-h post-dose efficacy of travoprost compared with latanoprost in patients with open-angle glaucoma. Curr Med Res Opin 24:3023–3027PubMedCrossRef

13.

Yildirim N, Sahin A, Gultekin S (2008) The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucoma. J Glaucoma 17:36–39PubMedCrossRef

14.

Viestenz A, Martus P, Schlötzer-Schrehardt U, Langenbucher A, Mardin CY (2004) Impact of prostaglandin-F(2alpha)-analogues and carbonic anhydrase inhibitors on central corneal thickness – a cross-sectional study on 403 eyes. Klin Monatsbl Augenheilkd 221:753–756PubMed

15.

Lass JH, Eriksson GL, Osterling L, Simpson CV, Latanoprost Corneal Effect Study Group (2001) Comparison of the corneal effects of latanoprost, fixed combination latanoprost-timolol, and timolol: a double-masked, randomized, one-year study. Ophthalmology 108:264–271PubMedCrossRef

16.

Brandt JD, Gordon MO, Beiser JA, Lin SC, Alexander MY, Kass MA (2008) Changes in central corneal thickness over time: the ocular hypertension treatment study. Ophthalmology 115:1550–1556PubMedCrossRef

17.

Harasymowycz PJ, Papamatheakis DG, Ennis M, Brady M, Gordon KD (2007) Relationship between travoprost and central corneal thickness in ocular hypertension and open-angle glaucoma. Cornea 26:34–41PubMedCrossRef

18.

Stefan C, Dumitrica DM, Tebeanu E, Nae I, Sapundgieva A, Dragomir L (2007) Prostaglandin analogues and central corneal thickness. Oftalmologia 51:95–99PubMed

19.

Sen E, Nalcacioglu P, Yazici A, Aksakal FN, Altinok A, Tuna T, Koklu G (2008) Comparison of the effects of latanoprost and bimatoprost on central corneal thickness. J Glaucoma 17:398–402PubMedCrossRef

20.

Hatanaka M, Vessani RM, Elias IR, Morita C, Susanna R Jr (2009) The effect of prostaglandin analogs and prostamide on central corneal thickness. J Ocul Pharmacol Ther 25:51–53PubMedCrossRef

21.

Johnson TV, Toris CB, Fan S, Camras CB (2008) Effects of central corneal thickness on the efficacy of topical ocular hypotensive medications. J Glaucoma 17:89–99PubMedCrossRef

22.

Johnson M, Kass MA, Moses RA, Crodzki WJ (1978) Increased corneal thickness simulating elevated intraocular pressure. Arch Ophthalmol 96:664–665PubMedCrossRef

23.

Whitacre MM, Stein R (1993) Sources of error with use of Goldmann-type tonometers. Surv Ophthalmol 38:1–30PubMedCrossRef

24.

Whitracre MM, Stein RA, Hassanein K (1993) The effect of corneal thickness on applanation tonometry. Am J Ophthalmol 115:592–596

25.

Brandt JD (2004) Corneal thickness in glaucoma screening, diagnosis, and management. Curr Opin Ophthalmol 15:85–88PubMedCrossRef

26.

Doughty MJ, Zaman ML (2000) Human corneal thickness and its impact on intraocular pressure measures: a review and meta-analysis approach. Surv Ophthalmol 44:367–408PubMedCrossRef

27.

Suh MH, Park KH, Kim DM (2009) Effect of travoprost on intraocular pressure during 12 months of treatment for normal-tension glaucoma. Jpn J Ophthalmol 53:18–23PubMedCrossRef

28.

Nomura Y, Nakamura S, Moriwaki M, Takahashi Y, Shiraki K (2010) Effect of travoprost on 24-hour intraocular pressure in normal tension glaucoma. Clin Ophthalmol 4:643–647PubMed

29.

Ang GS, Kersey JP, Shepstone L, Broadway DC (2008) The effect of travoprost on daytime intraocular pressure in normal tension glaucoma: a randomized controlled trial. Br J Ophthalmol 92:1129–1133PubMedCrossRef

30.

Ehlers N, Bramsen T, Sperling S (1975) Applanation tonometry and central corneal thickness. Acta Ophthalmol (Copenh) 53:34–43CrossRef

31.

Whitacre MM, Stein RA, Hassanein K (1993) The effect of corneal thickness on applanation tonometry. Am J Ophthalmol 115:592–596PubMed

32.

Brandt JD, Beiser JA, Kass MA, Gordon MO (2001) Central corneal thickness in the Ocular Hypertension Treatment Study (OHTS). Ophthalmology 108:1779–1788PubMedCrossRef

33.

Iester M, Mete M, Figus M, Frezzotti P (2009) Incorporating corneal pachymetry into the management of glaucoma. J Cataract Refract Surg 35:1623–1628PubMedCrossRef

34.

Sit AJ, Weinreb RN, Crowston JG, Kripke DF, Liu JH (2006) Sustained effect of travoprost on diurnal and nocturnal intraocular pressure. Am J Ophthalmol 141:1131–1133PubMedCrossRef

35.

Sharif NA, Kelly CR, Crider JY, Williams GW, Xu SX (2003) Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther 19:501–515PubMedCrossRef

36.

Miglior S, Albe E, Guareschi M, Mandelli G, Gomarasca S, Orzalesi N (2004) Intraobserver and interobserver reproducibility in the evaluation of ultrasonic pachymetry measurements of central corneal thickness. Br J Ophthalmol 88:174–177PubMedCrossRef

37.

Wickham L, Edmunds B, Murdoch IE (2005) Central corneal thickness: will one measurement suffice? Ophthalmology 112:225–228PubMedCrossRef

38.

Ornek K, Gullu R, Ogurel T, Ergin A (2008) Short-term effect of topical brinzolamide on human central corneal thickness. Eur J Ophthalmol 18:338–340PubMed

39.

Smith VA, Hoh HB, Littleton M, Easty DL (1995) Over-expression of a gelatinase A activity in keratoconus. Eye 9:429–433PubMedCrossRef

40.

Weinreb RN, Lindsey JD (2002) Metalloproteinase gene transcription in human ciliary muscle cells with latanoprost. Invest Ophthalmol Vis Sci 43:716–722PubMed

41.

Mietz H, Schlötzer-Schrehardt U, Strassfeld C, Krieglstein GK (2001) Effect of latanoprost and timolol on the histopathology of the rabbit conjunctiva. Invest Ophthalmol Vis Sci 42:679–687PubMed

42.

Sagara T, Gaton DD, Lindsey JD, Gabelt BT, Kaufman PL, Weinreb RN (1999) Topical prostaglandin F2alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch Ophthalmol 117:794–801PubMed

43.

Fellman RL, Sullivan EK, Ratliff M, Silver LH, Whitson JT, Turner FD, Weiner AL, Davis AA, Group TS (2002) Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial. Ophthalmology 109:998–1008PubMedCrossRef

44.

Camras CB (1996) Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology 103:138–147PubMed

45.

Peplinski LS, Albiani Smith K (2004) Deepening of lid sulcus from topical bimatoprost therapy. Optom Vis Sci 81:574–577PubMedCrossRef

46.

Yang HK, Park KH, Kim TW, Kim DM (2009) Deepening of eyelid superior sulcus during topical travoprost treatment. Jpn J Ophthalmol 53:176–179PubMedCrossRef

47.

Yam JC, Yuen NS, Chan CW (2009) Bilateral deepening of upper lid sulcus from topical bimatoprost therapy. J Ocul Pharmacol Ther 25:471–472PubMedCrossRef

Titel: Randomized crossover study of latanoprost and travoprost in eyes with open-angle glaucoma
verfasst von: Akira Sawada
Tetsuya Yamamoto
Naoyoshi Takatsuka
Publikationsdatum: 01.01.2012
Verlag: Springer-Verlag
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 1/2012
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-011-1762-1

Neu im Fachgebiet Augenheilkunde

08.04.2024 | Therapieverfahren in der Augenheilkunde | CME

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Randomized crossover study of latanoprost and travoprost in eyes with open-angle glaucoma

Abstract

Introduction

Methods

Results

Conclusions

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

Bestmögliche Wundheilung der Kornea dank optimaler pharmakologischer Therapie

Update Augenheilkunde

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Introduction

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2012

Ab externo laser photocoagulation for the treatment of spontaneous iris stromal cyst

Comparative study of vitrectomy versus intravitreous triamcinolone for diabetic macular edema on randomized paired-eyes

Nicotine reduces VEGF-secretion and phagocytotic activity in porcine RPE

Assessment of the reliability of endothelial cell-density estimates in the presence of pseudoguttata

Cryopreservation and long-term culture of transformed murine corneal endothelial cells

Biomedical ethics, 7th edition David DeGrazia, Thomas A. Mappes, Jeffrey Brand-Ballard: 2010, Softcover, 732pp, ISBN-9780073407456 £171.15 McGraw-Hill Incorporated

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

Bestmögliche Wundheilung der Kornea dank optimaler pharmakologischer Therapie

Update Augenheilkunde